Are you Dr. Riese?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 42 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
22 Chestnut Pl
Apartment 614
Brookline, MA 02445Phone+1 617-566-5516
Summary
- Dr. Richard Riese, MD is a pulmonologist in Brookline, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Brigham and Women's Faulkner Hospital.
Education & Training
Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 1995 - 1999
Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1995
Medical College of WisconsinClass of 1992
Certifications & Licensure
MA State Medical License 1994 - 2025
Clinical Trials
- Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants Start of enrollment: 2019 Dec 12
Publications & Presentations
PubMed
- Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.Jason J Luke, Sarina A Piha-Paul, Theresa Medina, Claire F Verschraegen, Mary Varterasian
Clinical Cancer Research. 2023-07-05 - 2 citationsPublisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.Marja K Puurunen, Jerry Vockley, Shawn L Searle, Stephanie J Sacharow, John A Phillips 3rd
Nature Metabolism. 2022-09-01 - 75 citationsSafety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.Marja K. Puurunen, Jerry Vockley, Shawn Searle, Stephanie Sacharow, John A. Phillips
Nature Metabolism. 2021-07-22
Press Mentions
- Synlogic Reports Third Quarter 2020 Financial Results and Provides Business UpdateNovember 5th, 2020
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business UpdateAugust 6th, 2020
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational ActivitiesMarch 30th, 2020- Join now to see all
Grant Support
- Cathepsins In Antigen Presentation And Lung ImmunityNational Institute Of Allergy And Infectious Diseases2003–2004
- Cathepsin S In MHC Class II Antigen PresentationNational Institute Of Allergy And Infectious Diseases1999–2003
